Michael Eggenberg - 15 Aug 2022 Form 4 Insider Report for Xtant Medical Holdings, Inc. (XTNT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
17 Aug 2022, 16:12:10 UTC
Prior SEC filing
17 Aug 2021
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Amy Culbert, attorney-in-fact

Key filing fact

Michael Eggenberg filed Form 4 for Xtant Medical Holdings, Inc. (XTNT) on 17 Aug 2022.

Key facts

  • This page summarizes Michael Eggenberg's Form 4 filing for Xtant Medical Holdings, Inc. (XTNT).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 17 Aug 2022, 16:12.

Change

  • Previous filing in this sequence was filed on 17 Aug 2021.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XTNT transaction

Common Stock, $0.000001 par value

Award

Transaction value
$0
Shares
+215,415
Change %
Price
$0.000000
Shares after
215,415
Date
15 Aug 2022
Ownership
Direct
Footnotes
F1, F2
XTNT holding

Common Stock, $0.000001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
56,004,974
Date
15 Aug 2022
Ownership
See Footnotes
Footnotes
F3, F4
XTNT holding

Common Stock, $0.000001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
17,109,618
Date
15 Aug 2022
Ownership
See Footnotes
Footnotes
F4, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 15, 2023, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date.

Footnote F2

The Reporting Person's Form 4 report filed on August 17, 2021 previously reported 120,549 shares that were subject to unvested restricted stock unit awards. These shares have vested and were transferred to each of ROS Acquisition Offshore LP ("ROS Acquisition") and OrbiMed Royalty Opportunities II, LP ("ORO II").

Footnote F3

These securities are held of record by ROS Acquisition. OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition as noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.

Footnote F4

Each of OrbiMed ROF II LLC ("ROF II"), Advisors and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes. The Reporting Person is an employee of Advisors.

Footnote F5

These securities are held of record by ORO II. ROF II is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors and ROF II may be deemed to have voting and investment power with respect to the securities held by ORO II as noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by ORO II.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .